Mutations in the breast cancer susceptibility gene (BRCA2) are believed to be responsible for a significant fraction of hereditary breast cancer. To determine the BRCA2 mutation spectrum in a subset of Swedish breast cancer families, 162 families were screened for germline mutations in this gene. A combination of RT-PCR, PTT and direct DNA sequencing was used. Two mutations and one previously reported polymorphic variant resulting in a truncated protein were identified. Our data suggest that only a small proportion of Swedish breast cancer families is attributable to BRCA2 germline mutations. This result, in combination with the low frequency of BRCA1 germline mutations identified in our previous study, suggests additional high penetrant as well as low penetrant breast cancer susceptibility genes are involved in familial breast cancer.
Introduction
Following the isolation of breast cancer susceptibility genes, BRCA1 at 17q21 1 and BRCA2 at 13q12-q13, 2, 3 great interest has been devoted to what extent mutations in these two genes are inherited. It was estimated at an early stage that 45-50% of breast cancer families had BRCA1 mutations 4 and about 35% BRCA2 mutations. 5 Most hereditary breast/ovarian cancer is explained by BRCA1 mutations, whilst male breast cancer families are over-represented among those with BRCA2 mutations. A recent review cites the estimated frequency of BRCA1 and BRCA2 mutations in breast cancer families in various countries. 6 The proportion of hereditary breast and ovarian cancer attributable to BRCA1 and BRCA2 mutations varies among populations, and some have common founder mutations, whereas others have not. BRCA1 mutations seem to be most common in Russia (79% of breast-ovarian families), 7 whilst a BRCA2 mutation is exceptionally common in Iceland. In the Ashkenazim, two founder mutations, BRCA1 185del AG and BRCA2 6174delT, each appear in the general population at approximately 1% frequency; a third mutation, BRCA1 5382insC, occurs at a population frequency of 0.11%. The Icelandic founder mutation, 999del5 in exon 9 of BRCA2, is a frameshift mutation leading to an early termination in codon 273 and a highly truncated protein. A mutation screen revealed this mutation in 16/21 Icelandic breast ovarian cancer families with the shared BRCA2 haplotype. It was found in 7.7% of female breast cancer patients and 40% of males with breast cancer in Iceland. 8, 9 The BRCA2 has a large coding sequence, composed of 26 exons that span 10 254 bp and encode a protein of 3418 amino acids. 3 More than 90% of disease-causing BRCA2 mutations result in a premature termination of translation or an absence of transcript (from Human Gene Mutation Database). The mutations are distributed throughout the gene without any clear evidence of clustering.
Since 1990 genetic counselling in cancer families has been offered to women in the Cancer Family Clinic at the Karolinska Hospital. All women with an increased risk of breast cancer based on family history have been offered screening. All families with increased risk (two or more close relatives with breast cancer regardless of age) have been invited to join our studies which aim to find the hypothetical genetic background for the increased risk. A blood sample has been obtained from at least one affected woman in each family willing to participate. Many studies have published frequencies of mutations in breast cancer families, usually with three or more affected women, and usually age of onset has been taken into consideration in the inclusion criteria. Since our criteria for increased risk has been based on earlier epidemiological studies, the majority of the families has few breast cancer cases and age of onset has not been used to exclude any family from the study. After cloning BRCA1, linkage data suggested that primary families with four or more cases of breast and/ or ovarian cancer would have mutations. We included all available families (127) with three or more cases in this first study and found mutations in nine families, eight in breast-ovarian families. 10 We have also an unpublished study on the families with only two cases of breast and/or ovarian cancer, which shows similar results, with mutations found only in families with breast and ovarian cancer, regardless of number of affected cases (unpublished data). Our results are similar to recent data based on clinical material. 11 When the BRCA2 was cloned we wanted to establish the frequency of BRCA2 mutations in the same cohort of patients. On this occasion we included all available patients, except those with BRCA1 mutations (9 in the first study and 6 in the following), but including those new patients who had been recruited after the BRCA1 studies.
We first paid special attention to the Icelandic founder mutation 999del5, to see whether that was also common in Sweden. Iceland was settled in the 9th century by people mainly of Scandinavian and Celtic origin. It is possible that this mutation is common in Scandinavian areas. It has been observed in two Finnish breast cancer families. 12 We examined a cohort of 222 patients from 222 families with hereditary breast or breast-ovarian cancer as described (3) . All patients were normal and thus none of these Swedish families showed the Icelandic founder mutation. It suggests that this founder mutation may not be of Swedish origin. Subsequently, we wanted to outline the BRCA2 germline mutation spectrum in Sweden. We selected PTT (protein truncation test), 13 a rapid and easy screening method which was expected to detect all truncating mutations, to evaluate the importance of BRCA2 in our samples.
Patients and Methods

Patients
The patients were recruited through a study of familial breast cancer in Stockholm in 1989 14 and through the cancer family clinic at Karolinska Hospital in Stockholm. The inclusion criteria were: at least two close relatives (first or second degree) with breast and/or ovarian cancer, regardless of age, and one affected relative willing to participate. The study was approved by the local ethical committee (no 89:144).
We examined 222 breast cancer patients from 222 families for the Icelandic 999del5 mutation. These included 129 families with three or more close relatives with breast or breast-ovarian cancer and 93 families with only two close breast cancer relatives.
The second part of the study looked at 162 patients who are part of the above cohort of 222 families. The type of family is shown in Table 1 . These families were screened for mutations by being divided into three groups. The first group included 74 families from whom DNA and RNA were available. The entire coding sequence was examined for BRCA2 mutation in these families. The second group consisted of 79 families where only DNA was available. The screening was only applied to exon 10 and 11 (60% of the BRCA2 coding sequence). The third group was composed of only 9 families where only RNA was available. We examined all exons except exons 10 and 11. Of these 162 families, 149 were screened for BRCA1 mutations and no mutation was found, 11 PTT Analysis BRCA2 has two large exons, exon 10 (1116 bp) and 11 (4929 bp), which represent 60% of the coding region. For these exons genomic DNA can be used as a PCR template. Exon 10 was amplified in one segment and exon 11 in four segments. Exons 2-9 and 12-27 were amplified in four segments because of their small sizes, and RT-PCR was needed to produce transcription templates for PTT. All the sequences of primers are given in To all the sense primers were added a T7 promoter sequence and translation start codon at their 5¢ end. The T7 promoter sequence is: 5¢-GCTAATACGACTCACTATAGGAACAGACCACCATGG-3¢. The primers for exon 10 and the antisense primer of fragment 11D are located in their corresponding introns.
was removed from a 1% low-melting agarose gel and purified using Wizard Minicolumns (Promega) before sequencing.
Results and Discussion
The BRCA2 was screened for germline mutations in breast cancer patients representing 162 families with increased risk for breast cancer ( Table 1 ). The entire coding sequence of BRCA2 gene was examined in 74 breast and/or ovarian cancer families and 60% of coding sequence (exon 10 and 11) was screened in 79 families. The other 9 families where only RNA was available were screened for all exons except exon 10 and 11 (Table 1) . Of these families, 149 has previously been screened for BRCA1 mutations and no mutation was found. We identified two germline mutations and one polymorphic variant (Table 3 ). The first mutation was found in a woman who had breast cancer at 72 years of age and was a member of a breast-ovarian cancer family (4064) (Figures 1, 2a, 3a) . It was a frameshift mutation in exon 11, 6819delTG, resulting in a loss of two bases in codon 2196, and a translation termination just four codons downstream. A second mutation was identified in a woman with breast cancer at 42 years of age from family 4081 (Figures 1, 2b, 3b) . It was a microdeletion of five bases in exon 10, 2024del5, also leading to a frameshift and an immediate stop. Both these mutations have previously been reported. 16 The polymorphic alteration identified in family 1416 is a base substitution in exon 27, leading to a change of AAA (Lys) to TAA (Ter) at codon 3326 (Figure 2c ). This variant results in the deletion of the last 93 amino acids of the BRCA2 protein. This alteration was reported recently to be a polymorphic stop codon. 17 In our family, two close relatives with breast cancer did not carry this variant. Neither did the patient carry the 6503delTT variant which was found sometimes on the same haplotype with ter3326 in breast cancer. 17 Inherited mutations in BRCA2 are believed to be responsible for a significant fraction of hereditary breast cancer. However, our study suggests quite a low frequency ( < 5%). The observed prevalance of BRCA2 mutations in our study may be underestimated, primarily since half (79/162) of the patients were only examined for 60% of the coding region.
Our mutational screening approach was not designed to identify uncommon missense mutations or possible mutations in the BRCA2 gene regulatory region. However, PTT detects all types of mutations, except missense mutations, and almost all clearly diseasecausing mutations identified so far in BRCA2 result in a premature termination of translation or an absence of transcript. Of these mutations, approximately 70% are small deletions, 15% small insertions and 10% base substitutions leading directly to termination codonsTEXTREF ID = "rf18" > 18 (from Human Gene Mutation Database). Occasional missense mutations and mutations resulting in splice errors have also been described, 12, 19, 20 but it is difficult at present to distinguish missense mutations from rare polymorphisms. In this study, exon 10 and 11 were screened using DNA, while the other exons used RNA-based screening. BRCA2 is expressed in lymphocytes to quite a low extent. It is also possible that some mutant transcript is absent or lower in abundance than its wild type counterpart and escapes from detection by PTT. This possibility, in combination with undetected missense mutations, may also contribute to an underestimated frequency.
We found only two mutations in the 162 families recruited because of an increased risk based on family history. Although we may have missed mutations, used wider inclusion criteria, and some families might be explained by non-genetic factors, we still believe that the figure is representative for this cohort of patients. A low incidence of BRCA2 mutations has also been reported in other populations. 6, [21] [22] [23] Epidemiological studies suggest an increased risk of breast cancer in our cohort of breast cancer families. We believe that many of these families have an increased risk of breast cancer based on a genetic factor. However, less than 10% (primarily in breastovarian cancer families) are attributable to mutations in BRCA1 and BRCA2. This implies that another gene or genes may be involved in the rest of familial breast cancers.
